Logo image
Back
Rituximab-induced serum sickness: A systematic review
Journal article   Peer reviewed

Rituximab-induced serum sickness: A systematic review

Paras Karmacharya, Dilli Ram Poudel, Ranjan Pathak, Anthony A. Donato, Sushil Ghimire, Smith Giri, Madan Raj Aryal and Clifton O. Bingham
Seminars in arthritis and rheumatism, v 45(3), pp 334-340
01 Dec 2015
DOI: https://doi.org/10.1016/j.semarthrit.2015.06.014
PMID: 26199061
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Life Sciences & Biomedicine Science & Technology Rheumatology
Objectives: To report a case of rituximab-induced serum sickness (RISS) and perform a systematic review and characterize RISS in autoimmune diseases and hematological malignancies. Methods: A comprehensive search of MEDLINE, EMBASE, ACR, and EULAR databases was performed for relevant articles of patients with RISS from inception to September 2014. Statistical analysis of demographic and clinical features was performed using Microsoft EXCEL 2007 and SPSS version 20.0. Results: In the 33 patients with RISS, the mean age of presentation was 39.1 +/- 17.5 yr with a female preponderance (n = 23, 76.67%). The majority of cases were associated with an underlying rheumatologic condition (n = 17, 51.5%), most commonly Sjogren's syndrome (n = 8, 44.4%). The classic triad of serum sickness (fever, rash, and arthralgia) was reported in 16 (48.5%) cases. Time from drug exposure to symptom onset was significantly greater with the first doses of rituximab compared to the second dose (mean time 10.00 vs. 4.05 d, P = 0.002), and time to resolution was significantly greater for rheumatologic vs. hematological indications (mean time 2.50 vs. 1.00 d, P = 0.035). Corticosteroids were the most commonly used treatment (n = 21), with all cases reporting a complete resolution of symptoms in 2.15 +/- 1.34 d. Conclusion: It is important to recognize RISS clinically, as it may mimic exacerbation of various rheumatologic conditions. Although RISS is typically self-limited, further infusions of rituximab should be avoided, as it may provoke more severe symptoms. (C) 2015 Elsevier Inc. All rights reserved.

Metrics

1 Record Views
99 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Rheumatology
Logo image